[Mitomycin, vindesine and cisplatin combination therapy in the treatment of advanced non-small cell lung cancer: a report of 108 cases].
OBJECTIVE
To evaluate the results of combination chemotherapy with mitomycin (MMC), vindesine (VDS) and cisplatin (DDP) in patients with advanced non-small cell lung cancer (NSCLC).


METHODS
A total of 108 patients with advanced NSCLC was enrolled in this study. Adenocarcinoma (74 cases) and squamous-cell carcinoma (23 cases) were the most common type of malignancy. Thirty patients received prior chemotherapy while 78 did not.


RESULTS
Complete response was observed in 1 patient and partial response in 36 patients with an overall response rate (RR) of 34.3%. The RR was significantly higher in the previously untreated patients (41.0%) and than that in the pretreated patients (P = 0.0169). The RR did not significantly differ between patients with squamous--cell carcinoma (30.4%) and adenocarcinoma (32.4%). That of patients with metastases to the lymph nodes, to the other parts of lung, liver and bone was 43.1%, 32.4%, 25.0% and 0, respectively. The median response duration was 3 months and the median survival period was 7 months. The dose limiting toxicity was neutropenia, which was in grade III and IV in 41.7% of the treated patients. Grade III and IV thrombocytopenia was observed in 6.5% and grade III and IV nausea and vomiting in 21.3% of the treated patients.


CONCLUSIONS
A higher response rate is attainable in patients with advanced NSCLC treated by MMC, VDS and DDP with tolerable toxicity.
Zhang
X
X
Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021.
Sun
Y
Y
Feng
F
F
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects; D015996:Survival Rate; D014751:Vindesine / Q000008:administration & dosage / Q000009:adverse effects
D016685:Mitomycin; D002945:Cisplatin; D014751:Vindesine